Drugs / MANP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06343298 Comparator | Nov 2024 → Jul 2026 overdue | resistant hypertension | E-Star BioTech, LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MANP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06343298 ↗ |
| Modality | Peptide | “MANP (modified atrial natriuretic peptide) is a peptide” NCT06343298 ↗ |
| Route | Subcutaneous | “SUBCUTANEOUS MANP when administered once daily” NCT06343298 ↗ |